Ardelyx, Inc. (ARDX) NASDAQ
5.78
+0.12(+2.12%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.78
+0.12(+2.12%)
Currency In USD
| Previous Close | 5.66 |
| Open | 5.7 |
| Day High | 5.9 |
| Day Low | 5.65 |
| 52-Week High | 8.4 |
| 52-Week Low | 3.21 |
| Volume | 2.74M |
| Average Volume | 4.64M |
| Market Cap | 1.42B |
| PE | -22.23 |
| EPS | -0.26 |
| Moving Average 50 Days | 6.85 |
| Moving Average 200 Days | 5.62 |
| Change | 0.12 |
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
GlobeNewswire Inc.
Mar 09, 2026 8:05 PM GMT
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatmentWALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Arde
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrowDAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: AR
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class